Peptide Patent US12612430B2, Enlitisa (Shanghai) Pharmaceutical
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Peptides
Grant US12612430B2 Kind: B2 Apr 28, 2026
Assignee
ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD.
Inventors
Jan-Christer Janson, Ming Gu, Bengt Ingemar Samuelsson, Maoqian Song
Abstract
Provided is a peptide compound comprising the amino acid sequence: Xaa1-Lys-Xaa3-Ser-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13 wherein: Xaa1 represents Ala or Ser, or is absent, wherein the N-terminal amino acid optionally includes an N-terminal 3,4-dihydrocinnamic acid group; Xaa5 represents Tyr, DOPA or a single bond; Xaa3 and Xaa6 independently represent Pro, Hyp or diHyp; Xaa7, Xaa8, Xaa9, Xaa10, and Xaa11 are each optional (in which case Xaa6 is bonded to Xaa12), and are independently selected from the group Pro, Hyp, diHyp, Thr, DOPA and Tyr; Xaa12 represents Pro, Hyp, diHyp, Thr, DOPA or Tyr; and Xaa13 represents Lys or is absent, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said peptide compound, provided that when the N-terminal 3,4-dihydrocinnamic acid group is not present, Xaa1 represents Ala or is absent and Xaa13 represents Lys, then Xaa12 represents Pro, Hyp, diHyp or Thr. The compounds are particularly useful in for treatment of conditions characterised by inflammation, including wounds, burns, and disorders of the mucosa, such as anorectal diseases, inflammatory bowel diseases, gynaecological diseases and dental diseases.
CPC Classifications
C07K 7/06 A61P 29/00 A61K 8/64
Filing Date
2020-09-11
Application No.
17642764
Claims
22
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.